- Home
- MAIA vs ANVS Comparison
MAIA vs ANVS Comparison
Compare MAIA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | ANVS |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 111.3M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MAIA | ANVS |
|---|---|---|
| Price | $1.47 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | ★ 1.2M | 382.0K |
| Earning Date | 05-08-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.53 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $1.11 |
| 52 Week High | $3.19 | $5.50 |
Technical Indicators
Market Signals| Indicator | MAIA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 42.74 |
| Support Level | $1.44 | $2.29 |
| Resistance Level | $1.46 | $2.99 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 34.88 | 14.68 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.